Metropolitan Life Insurance CO Design Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.5 - $9.77 $1,281 - $2,276	-233 Reduced 10.36%	2,016 $11,000
Q4 2022 Jun 14, 2023	BUY	$7.86 - $17.2 $1,831 - $4,007	233 Added 11.56%	2,249 $23.1 Million
Q4 2022 Mar 30, 2023	BUY	$7.86 - $17.2 $1,744 - $3,818	222 Added 10.95%	2,249 $23,000
Q4 2022 Feb 15, 2023	BUY	$7.86 - $17.2 $1,744 - $3,818	222 Added 10.95%	2,249 $23,000
Q3 2022 Jun 14, 2023	BUY	$14.09 - $25.57 $154 - $281	11 Added 0.55%	2,027 $33.9 Million
Q2 2022 Jun 20, 2023	BUY	$9.91 - $17.33 $109 - $190	11 Added 0.55%	2,027 $28,000
Q1 2022 Jun 20, 2023	BUY	$11.17 - $20.89 $122 - $229	11 Added 0.55%	2,027 $32,000
Q1 2022 Mar 30, 2023	SELL	$11.17 - $20.89 $67,254 - $125,778	-6,021 Reduced 74.81%	2,027 $32,000
Q1 2022 May 12, 2022	SELL	$11.17 - $20.89 $67,254 - $125,778	-6,021 Reduced 74.81%	2,027 $33,000
Q4 2021 Jun 21, 2023	BUY	$13.64 - $21.41 $82,276 - $129,145	6,032 Added 299.21%	8,048 $172,000
Q4 2021 Mar 30, 2023	BUY	$13.64 - $21.41 $79,098 - $124,156	5,799 Added 257.85%	8,048 $172,000
Q4 2021 Feb 15, 2022	BUY	$13.64 - $21.41 $109,774 - $172,307	8,048 New	8,048 $172,000

102

31M

2.3K

16.5K

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $347M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.